Tenax Therapeutics (TENX) Cash & Equivalents (2010 - 2026)

Tenax Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $118.0 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $118.0 million, up 11.87% year-over-year; the trailing twelve-month figure through Jun 2026 was $118.0 million (up 11.87% YoY), and the FY2025 annual result was $97.6 million, up 2.86% from the prior year.
• Cash & Equivalents slipped to $118.0 million in Q2 2026, from $118.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $118.8 million in Q1 2026 and troughed at $2.1 million in Q4 2022.
• A 5-year average of $51.7 million and a median of $13.9 million in 2023 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 61.96%; it then soared 1023.85% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $2.1 million in 2022, then soared by 361.02% to $9.8 million in 2023, then jumped by 868.66% to $94.9 million in 2024, then gained by 2.86% to $97.6 million in 2025, then advanced by 20.92% to $118.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $118.0 million in Q2 2026, $118.8 million in Q1 2026, and $97.6 million in Q4 2025.